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Abstract. Influenza viruses represent a serious threat to 
human health. Although our research group has previously 
demonstrated the antiviral and anti‑inflammatory activities 
of eleutheroside B1, a detailed explanation of the mechanism 
by which it is effective against the influenza virus remains 
to be elucidated. In the present study, the transcriptomic 
responses of influenza A virus‑infected lung epithelial cells 
(A549) treated with eleutheroside B1 were investigated using 
high-throughput RNA sequencing, and potential targets were 
identified using a molecular docking technique, reverse tran-
scription-quantitative polymerase chain reaction (RT-qPcR) 
assay, and dNA methylation analysis. The transcriptomic 
data revealed that there are 1,871 differentially expressed 
genes (DEGs) between the cells infected with the influenza 
virus strain variant PR8, and the cells infected with PR8 and 
treated with eleutheroside B1. Among the dEGs, RNA poly-
merase II subunit A (POLR2A; encoding the largest subunit 
of RNA polymerase II) and mannosidase α class II member 1 
(MAN2A1) were selected from the molecular docking analysis 
with eleutheroside B1. The docking score of Drosophila mela‑
nogaster MAN2A1 (3BVT) was 11.3029, whereas that of 
POLR2A was 9.0133. The RT-qPcR results demonstrated that 
the expression levels of host genes (MAN2A2, POLR2A) and 
viral genes (PA, PB1, PB2, HA) were downregulated following 
eleutheroside B1 treatment. Bisulfite-sequencing PcR was 
performed to investigate whether eleutheroside B1 was able 
to modify the dNA methylation of POLR2A, and the results 
suggested that the average proportion of methylated cpGs 
(‑222‑72 bp) increased significantly following treatment with 
eleutheroside B1. Taken together, these findings suggested 
that eleutheroside B1 may affect N-glycan biosynthesis, the 
chemokine signaling pathway, cytokine‑cytokine receptor 
interaction and, in particular, may target the POLR2A to 
inhibit the production of influenza virus genes.
Introduction
Influenza A viruses cause worldwide outbreaks of influenza and 
seasonal pandemics, and pose serious risks to public health (1). 
Influenza A viruses belong to the Orthomyxoviridae family, 
with a negative single-stranded, segmented RNA genome, and 
have been categorized into different subtypes on the basis of 
their hemagglutinin and neuraminidase antigens (2). Their 
negative-sense RNA genomes have no proof-reading mecha-
nism during replication, so they are extremely error-prone, 
giving rise to a high mutation rate (3). Therefore, it is a lengthy 
process to update the matched vaccine for these quickly modi-
fying viruses, and it is necessary to continually develop novel 
effective antiviral drugs against influenza viruses in order to 
prepare for the continual seasonal outbreaks.
Currently available anti‑influenza virus drugs target the 
viral life cycle, including amantadine, rimantadine, oselta-
mivir, zanamivir and peramivir. However, prolonged treatment 
and the resulting immuno-compromised status of patients 
lead to increases in drug‑resistant mutations among influenza 
viruses worldwide (4). Previous studies have indicated that 
the influenza strains H3N2 and pdmH1N1 are resistant to 
adamantanes (5), and the latest outbreak of the H7N9 virus 
is also resistant to oseltamivir (6). On the other hand, novel 
antiviral drugs derived from traditional chinese medicine 
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(TcM) do not tend to lead to the development of drug resis-
tance among the viruses so easily. Therefore, numerous studies 
have focused on developing anti‑influenza drugs using natural 
resources, such as traditional medicines, which offer hopeful 
new prospects for influenza management (1,7).
coumarin is a fragrant organic chemical compound of the 
benzopyrone chemical class that is a natural substance found 
in many plant species, which exhibits a variety of potent phar-
macological activities, including antioxidant, antibacterial, 
anti‑inflammatory, antitumor and antiviral activities (8‑13). 
Previous studies by our research group have demonstrated that 
eleutheroside B1, a coumarin compound, has a wide spectrum 
of anti‑human influenza virus efficacy, with an IC50 value (i.e., 
the concentration which leads to half-maximal inhibition) of 
64-125 µg/ml in vitro, and it inhibited the mRNA expression 
of several chemokine genes and the influenza nucleoprotein 
(NP) gene, while exhibiting low cytotoxicity (14).
Over the past few decades, computational chemistry, molec-
ular biology, pharmacognosy and biotechnology have become 
major scientific areas for the research of natural products. Some 
modern technologies, including RNA sequencing and molecular 
docking, have also been used to identify novel molecules for the 
effective treatment of diseases, and to investigate the underlying 
mechanisms of action and the specific targets, as well as DNA, 
RNA, protein and enzyme interactions, associated with natural 
products (15). RNA sequencing is a genome-wide analytical 
technology that has been used to analyze the transcriptome 
of the host response to human or avian influenza virus infec-
tion (16,17). A previous study has also used this technology to 
provide a comprehensive analysis of the pharmacological effects 
of natural products (18). The molecular docking approach 
has become an increasingly important tool in pharmaceutical 
research, and can be used to model the interaction between a 
small molecule and a protein at the atomic level, which enables 
the identification of potential drug targets, as well as the ability 
to characterize the behavior of small molecules in the binding 
site of target proteins (19). In the present study, the pathway 
profiles of influenza A virus‑infected lung epithelial (A549) 
cells following eleutheroside B1 treatment were assessed, which 
has enabled us to gain a comprehensive understanding of the 
mechanism of eleutheroside B1 activity against influenza A viral 
infection. From the RNA sequencing results, it was determined 
that eleutheroside B1 may exert its pharmacological effects 
on multiple targets, including the immune system, the glycan 
biosynthesis and metabolism pathways, signaling molecules and 
their interactions, transcriptional regulation of the chemokine 
signaling pathway, various types of N-glycan biosynthesis, and 
cytokine‑cytokine receptor interaction. A molecular docking 
approach was subsequently used to investigate the potential 
target receptor proteins for eleutheroside B1. Finally, a variety 
of molecular biology techniques, including reverse transcrip-
tion-quantitative polymerase chain reaction (RT-qPcR) assay, 
bisulfite treatment and DNA methylation analyses, were used 
to evaluate the results from the RNA sequencing and molecular 
docking experiments.
Materials and methods
Compounds, cells and viruses, and software. Eleutheroside B1 
was purified from Sarcandra glabra extract (Si chuan, china) 
and characterized by high-resolution mass spectrometry and 1H 
and 13c nuclear magnetic resonance spectroscopy, as described 
previously (13). The purity of the compound exceeded 98%, 
according to analysis by ultra-performance liquid chroma-
tography/time‑of‑flight mass spectrometry. Eleutheroside B1 
was dissolved in dimethyl sulfoxide (Sigma‑Aldrich; Merck 
KGaA, Darmstadt, Germany) as a stock solution of 50 mg/ml, 
and stored at ‑20˚C until use. A549 cells were purchased 
from the American Tissue culture collection (ATcc; 
Manassas, VA, USA). The cells were grown in dulbecco's 
modified Eagle's medium with 10% fetal bovine serum under 
standard conditions at 37˚C in 5% CO2 humidified air. The 
influenza virus strain A/PR/8/34 (H1N1) was also purchased 
from ATCC. The influenza viruses were propagated in the 
allantoic cavities of chicken eggs. ORCID iD of ChemDraw 
Ultra 8.0 and SYBYL-X2.1.1 software was used in this study 
(no. 0000‑0003‑1628‑7416), kindly provided by Dr Xin‑An 
Huang (Tropical Medicine Institute, Guangzhou University of 
chinese Medicine, Guangzhou, china).
Cell culture, virus infection and sample preparation. The 
A549 cells were grown in a monolayer up to 80% confluency 
and detached from the flask using 10 mM EDTA (pH 7.4) and 
0.25% trypsin. The cells were harvested, and 6x105 A549 cells 
were seeded in 6-well tissue culture plates. On the following 
day, the cells were washed twice with PBS and infected with 
A/PR/8/34 [H1N1; 0.1 multiplicity of infection (MOI)] using 
serum‑free medium for 2 h at 37˚C. The inoculum was removed, 
and the cells were treated with or without eleutheroside B1 at 
a concentration of 100 µg/ml (14). At 24 h post-infection, the 
cells were lysed in TRIzol reagent (Thermo Fisher Scientific, 
Inc., Waltham, MA, USA) and stored at ‑80˚C.
RNA isolation, cDNA library construction and sequencing. 
Total RNA extracts from each sample were obtained with 
Table I. Primer sequences.
Gene Primer Sequence (5'-3')
PA Forward AcAcTAcAGGGGcTGAGAAA
 Reverse TGAAcGAGAAAATGTGGATG
PB1 Forward AGTTTTGGTGTGTcTGGGA
 Reverse TTcGGGTTTGTATTTGTGTG
PB2 Forward AcccAGATGAAGGcAcAG
 Reverse TAGAGTcccGTTTTcGTTTc
POLR2A Forward GATGAAcTGAAGcGAATGTcT
 Reverse GTcGTcTcTGGGTATTTGATG
HA Forward TGAAcAGGGAAAAGGTAGATG
 Reverse cAGGGAGAccAAAAGcAc
MAN2A2 Forward GcccTcATTTTcTGTTTATTG
 Reverse cTGcccTATTTAcccATcAc
GAPdH Forward GcTGAGTATGTTGTGGAGTc
 Reverse GcAGAAGGAGcAGAGATGA
POLR2A, RNA polymerase II subunit A; HA, hemagglutinin; 
MAN2A1, mannosidase α class II member 1.
INTERNATIONAL JOURNAL OF MOLEcULAR MEdIcINE  42:  2776-2792,  20182778
TRIzol reagent, according to the manufacturer's instruc-
tions (Thermo Fisher Scientific, Inc.). The total RNA quality 
was analyzed using agarose electrophoresis (1% gels). The 
A260/A280 ratio was determined using a Nanodrop spectropho-
tometer (NanoDrop Technologies; Thermo Fisher Scientific, 
Inc.). RNA integrity was assessed by Agilent 2100 TapeStation 
analysis (Agilent Technologies, Santa clara, cA, USA). An 
A260/A280 ratio between 1.8 and 2.0 and an RNA integrity 
number >7 were considered acceptable parameters for RNA 
integrity. RNA sequencing was performed on an Illumina 
X-ten RNA-Seq sequence production system (Illumina, Inc., 
San diego, cA, USA).
Pathway analysis of differentially expressed genes (DEGs). 
In order to obtain a list of dEGs, Gene Ontology (GO) and 
pathway enrichment analyses were performed. In addition, 
GO terms, Interpro (protein sequence analysis and classifica-
tion) terms, and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) pathways that were significantly enriched on our 
list of genes with altered expression (P<0.05) were identified. 
Additionally, the integrated pathways with statistical values 
were computed from our list of dEGs using a reactome 
pathway analysis (http://www.reactome.org/). For over-repre-
sentation analysis, the number of altered genes associated with 
a pathway was compared between the treatment and control 
groups. To determine pathway perturbation, the significance of 
a particular gene to a pathway was considered in determining 
the overall impact on the pathway by examining all annotated 
functions/interactions of the gene.
Targeting and molecular optimization. Two-dimensional 
[2d(a)] and three-dimensional [3d(b)] structural information 
of the compound were obtained from the National centre 
for Biotechnology Information (NcBI; (https://pubchem.
ncbi.nlm.nih.gov/compound/12302276#section=Top), and 
these were saved as mol.2 files. The 3D‑formatted molecule 
was imported into the Pharmaceutical Target Seeker (PTS; 
http://www.rcdd.org.cn/PTS/result), and a search was 
conducted. Molecular modeling was conducted with the 
SYBYL program package (20). Eleutheroside B1 was used 
as the template. Its conformation was searched and identified 
by energy minimization using the MMFF94 force field with 
the Powell conjugate gradient minimization algorithm, and a 
convergence criterion of 0.005 kcal/(mol•Å). The MMFF94 
charge was used to calculate partial atomic charges. The 
parameters were set as defaults.
Protein preparation and docking. Through the PTS, select 
proteins were identified that were potentially matched with 
eleutheroside B1. Given our goal of attempting to find a poten-
tial target of eleutheroside B1 that would be effective against 
the influenza virus, and considering our previous results, Golgi 
mannosidase α class II member 1 (MAN2A1) and RNA poly-
merase II subunit A (POLR2A) were selected as candidate 
targets. The four-letter PdB code (3BVT) of Drosophila mela‑
nogaster MAN2A1 (with resolution at 1.3 Å) and the PDB 
code (3d9N) of POLR2A (with resolution at 1.60 Å) were 
retrieved from the Protein Data Bank (PDB; http://www.
pdb.org/pdb/home/home.do). Structural optimization of the 
protein was conducted using SYBYL software. The crystal 
structure of D. melaogaster MAN2A1 was subjected to geom-
etry optimization using the Swiss PdB viewer v4.1.0 program. 
The compound structure of eleutheroside B1 was prepared 
for docking using ChemDraw Ultra 8.0 and SYBYL‑X2.1.1 
software. The execution of molecular docking analysis and 
visualization were conducted using Surflex‑Dock software. 
The removal of solvent molecules, hydrogen addition, and 
the AMBER7 FF99 charges calculation were performed. 
Furthermore, all default parameters were used for docking 
simulations by SYBYL Vina analysis.
RT‑qPCR assay. A549 cells were seeded in 6-well plates at 
37˚C in an atmosphere of 5% CO2, then infected with influ-
enza virus (strain A/PR/8/34; 0.1 MOI) and subsequently 
treated with eleutheroside B1 at a diluted concentration. At 
24 h post-infection, the cells were collected for mRNA expres-
sion analysis of the host genes (MAN2A2, POLR2A) and the 
viral genes [polymerase acid (PA), polymerase basic (PB) 1 
and 2 and hemagglutinin (HA)] by RT-qPcR. Total RNA was 
extracted using TRIzol reagent (Invitrogen; Thermo Fisher 
Scientific, Inc.). Total RNA (1 µg) was reverse transcribed 
into cDNA using the Prime‑Script RT‑PCR kit (Takara 
Biotechnology Co., Ltd., Dalian, China) at 37˚C for 15 min, 
85˚C for 5 sec. The samples were amplified in SYBR Green 
qPcR buffer (ABP Biosciences, Jiemei long biological co., 
Ltd., Wuhan, china). qPcR was performed using an ABI7500 
Real-time PcR System (Applied Biosystems; Thermo Fisher 
Scientific, Inc.) with the following thermocycling conditions: 
95˚C for 3 min, followed by 40 cycles of 95˚C for 5 sec and 
60˚C for 30 sec (16). Relative gene (PA, PB1, PB2, HA, 
POLR2A, MAN2A2 and GAPdH) expression levels were 
calculated using the 2-ΔΔcq method (21). Primer sequences are 
listed in Table I.
CpG island (CGI) prediction. A Hidden Markov Model 
(HMM)-based cGI prediction for the MAN2A1 and POLR2A 
gene loci was obtained from the browser (http://www.urogene.
org/cgi-bin/methprimer/methprimer.cgi) (22).
Table II. RNA-seq overview: Reads mapping quality summary.
Sample Total Total Mapped Mapped Proper  MAPQ≥5 Discordantly
name reads bases reads rate (%) paired mapped Singletons rate (%) mapped
A549 34753376 5.21E+09 33748010 97.11 33748010 0 95.26 0
PR8 33971006 5.1E+09 32589740 95.93 32589740 0 94.10 0
PR8+eleu 34797038 5.22E+09 33215018 95.45 33215018 0 93.40 0
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Table III. Significantly enriched GO terms in response to eleutheroside B1.
GO description P-value Number of genes 
Oxidoreductase activity, acting on the cH-NH group of donors, NAd or NAdP as acceptor 0.001378 6
Heterocycle biosynthetic process 0.001468 119
Aromatic compound biosynthetic process 0.001584 118
Organic cyclic compound biosynthetic process 0.001615 119
Oxidoreductase activity, acting on the cH-NH group of donors 0.002303 6
dNA ligase activity 0.002306 4
dNA ligation 0.002306 4
dNA ligase (ATP) activity 0.002306 4
Binding 0.002597 754
Molecular function 0.002715 952
Intra-Golgi vesicle-mediated transport 0.003632 6
Establishment of protein localization to Golgi 0.003993 5
Protein targeting to Golgi 0.003993 5
Retrograde transport, vesicle recycling within Golgi 0.003993 5
Protein localization to Golgi apparatus 0.003993 5
Double‑stranded RNA‑specific ribonuclease activity 0.004917 4
Ribonuclease III activity 0.004917 4
Methylenetetrahydrofolate dehydrogenase (NAdP+) activity 0.004917 4
Negative regulation of transcription, dNA-templated 0.005146 5
Negative regulation of gene expression 0.005146 5
Negative regulation of nucleic acid-templated transcription 0.006515 5
Negative regulation of RNA metabolic process 0.006515 5
Negative regulation of RNA biosynthetic process 0.006515 5
Ligase activity, forming phosphoric ester bonds 0.006757 4
Nucleobase-containing compound biosynthetic process 0.007534 110
RNA phosphodiester bond hydrolysis, endonucleolytic 0.00998 5
Endoribonuclease activity 0.00998 5
NAdP biosynthetic process 0.010598 3
NAD+ kinase activity 0.010598 3
Formate-tetrahydrofolate ligase activity 0.010598 3
Regulation of neurotransmitter levels 0.011107 2
Argininosuccinate synthase activity 0.011107 2
Methylenetetrahydrofolate reductase (NAd(P)H) activity 0.011107 2
Gamma-tubulin binding 0.011107 2
Pteridine-containing compound biosynthetic process 0.011677 4
Folic acid-containing compound biosynthetic process 0.011677 4
Folic acid-containing compound metabolic process 0.011677 4
dNA topoisomerase type I activity 0.015169 3
Ligase activity, forming carbon-nitrogen bonds 0.015411 9
Regulation of Ras protein signal transduction 0.016281 16
Ras protein signal transduction 0.016281 16
regulation of cellular process 0.016648 193
Ion binding 0.016903 192
Regulation of small GTPase mediated signal transduction 0.017061 18
Regative regulation of cellular macromolecule biosynthetic process 0.017259 5
Regulation of developmental process 0.017259 5
Metal ion binding 0.017719 188
Endoribonuclease activity, producing 5'-phosphomonoesters 0.018441 4
NAdP metabolic process 0.018441 4
cation binding 0.019467 188
Regulation of biological process 0.019795 193
Negative regulation of biosynthetic process 0.020303 5
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Table III. continued.
GO description P-value Number of genes 
Negative regulation of cellular biosynthetic process 0.020303 5
Negative regulation of nitrogen compound metabolic process 0.020303 5
Negative regulation of nucleobase-containing compound metabolic process 0.020303 5
Negative regulation of macromolecule biosynthetic process 0.020303 5
dNA-directed RNA polymerase II, core complex 0.021299 2
Pteridine-containing compound metabolic process 0.022568 4
Exonuclease activity 0.023676 5
Biological regulation 0.02412 201
Heterocycle metabolic process 0.024922 168
cellular aromatic compound metabolic process 0.025948 168
Quanyl-nucleotide exchange factor activity 0.02599 18
Sulfur compound transmembrane transporter activity 0.027145 3
Organic cyclic compound metabolic process 0.028103 168
cellular nitrogen compound biosynthetic process 0.028363 129
ARF guanyl-nucleotide exchange factor activity 0.031456 5
Regulation of ARF protein signal transduction 0.031456 5
ARF protein signal transduction 0.031456 5
GdP binding 0.031599 18
Hydrolase activity, acting on ester bonds 0.031838 40
Regulation of intracellular signal transduction 0.031966 19
Transmembrane receptor protein serine/threonine kinase activity 0.032389 4
Regulation of multicellular organismal development 0.032389 4
Taurine transmembrane transporter activity 0.034046 2
Negative regulation of blood vessel morphogenesis 0.034046 2
calcium-dependent protein binding 0.034046 2
Taurine:sodium symporter activity 0.034046 2
Negative regulation of angiogenesis 0.034046 2
Histamine receptor activity 0.034046 2
Negative regulation of vasculature development 0.034046 2
Neurotransmitter transporter activity 0.034554 3
Neurotransmitter:sodium symporter activity 0.034554 3
Mannose metabolic process 0.034554 3
Organic acid:sodium symporter activity 0.034554 3
Hormone receptor binding 0.0381 4
Wnt signaling pathway 0.0381 4
Nuclear hormone receptor binding 0.0381 4
Molecular function regulator 0.038432 32
dNA biosynthetic process 0.039752 6
Phosphatase regulator activity 0.040667 5
Intrinsic component of plasma membrane 0.040951 7
Integral component of plasma membrane 0.040951 7
dNA topological change 0.042894 3
Aspartate family amino acid metabolic process 0.042894 3
Signal transduction 0.042957 97
coenzyme biosynthetic process 0.044016 8
Pyridine nucleotide biosynthetic process 0.044349 4
Pyridine-containing compound biosynthetic process 0.044349 4
Nicotinamide nucleotide biosynthetic process 0.044349 4
Anatomical structure morphogenesis 0.044349 4
Single organism signaling 0.044355 97
cellular response to stimulus 0.045164 111
Signaling 0.046516 97
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Bisulfite treatment and DNA methylation analysis. Genomic 
dNA was extracted from eleutheroside B1-treated and 
non‑treated A549 cells following an influenza virus infection 
using a DNA Extraction of Cell and Tissue kit (cat. no. GK0122; 
Generay Biotech Co., Ltd., Shanghai, China). The bisulfite 
conversion was performed with 1 µg genomic dNA using an 
EpiTect Fast DNA Bisulfite kit (cat. no. 59824; Qiagen China 
co., Ltd., Shanghai, china), according to the manufacturer's 
instructions. The bisulfite‑modified DNA was amplified by 
PcR with primers that were designed to cover two regions 
One primer extended from -545 bp upstream and -213 bp 
downstream to the transcription start site of MAN2A1, 
whereas the other extended from -199 bp upstream and 139 bp 
downstream. For the POLR2A gene, 66 cpG sites ranging 
from -606 to +476 bp relative to exon 1 in a cpG island were 
selected for subsequent analysis, and for the design of primers. 
Subsequently, the first‑stage PCR product was amplified 
under the following conditions: 95˚C for 4 min; 40 cycles 
Table III. continued.
GO description P-value Number of genes 
Transcription, dNA-templated 0.048815 90
IMP dehydrogenase activity 0.048989 2
Negative regulation of developmental process 0.048989 2
Nucleoside phosphate biosynthetic process 0.049767 13
Nucleotide biosynthetic process 0.049767 13
GO, Gene Ontology.
Figure 1. KEGG pathways enriched in response to eleutheroside B1 treatment. Enrichment analysis results of dEGs between the eleutheroside B1 treatment 
group (PR8 + eleu) and the virus-infected alone group (PR8). dEG, differentially expressed gene; KEGG, Kyoto Encyclopedia of Genes and Genomes.
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of 94˚C for 30 sec, 55˚C for 30 sec, and 72˚C for 40 sec, 
followed by a final extension at 72˚C for 5 min. PCR products 
were purified using a PCR purification kit (cat. no. GK2043; 
Generay Biotech co., Ltd.). The PcR products were cloned 
into the TA cloning vector (cat. no. GV6021; Generay Biotech 
co., Ltd.). Ten clones from each donor were sequenced using 
an M13 reverse primer.
Statistical analysis. All data are expressed as the mean ± stan-
dard deviation of at least three separate experiments. differences 
between two groups were analyzed using Student's t-test, 
whereas differences between multiple groups were analyzed 
using one-way analysis of variance followed by Fisher's Least 
Significant Difference post‑hoc test. Statistical analyses were 
performed using SPSS 18.0 (SPSS, Inc., chicago, IL, USA). 
P<0.05 was considered to indicate a statistically significant 
difference.
Results
Sequencing and alignment. To investigate the molecular 
mechanism of eleutheroside B1 action against influenza A 
virus infection, RNA sequencing of influenza A virus‑infected 
human lung epithelial A549 cells, in the presence or absence 
of eleutheroside B1 treatment, was performed using an 
Illumina X-ten RNA-seq sequence production system. The 
RNA sequences were subsequently aligned against the 
human gene sequences. Three different experimental groups 
were established: Lung epithelial A549 cells without infec-
tion (A549 group), A549 cells infected with influenza strain 
A/PR8/34/(H1N1) alone (PR8 group), and A549 cells both 
infected with A/PR8/34/(H1N1) and treated with 100 µg/ml 
eleutheroside B1 (PR8 + eleu group). At 24 h after the influ-
enza virus infection, samples were harvested and subjected 
to library construction and RNA sequencing. An excess of 
13 million raw reads for each sample were generated from 
the constructed RNA sequencing libraries using the Illumina 
X-ten RNA-seq sequence production system. After strin-
gent data filtering, 34.75 M (97.11%; A549 group), 33.97 M 
(95.93%; PR8 group), or 34.79 M (95.45%; PR8 + eleu group) 
sequencing reads could be unambiguously mapped against the 
reference genome (Table II), which confirmed the high quality 
of the sequencing of these samples, and a satisfactory variable 
for subsequent analyses.
Figure 2. Enrichment analysis results of DEGs regulated by eleutheroside B1 treatment in cytokine‑cytokine receptor interactions pathway. The heat‑map 
shows the 12 DEGs that were regulated by eleutheroside B1 treatment among three samples in the cytokine‑cytokine receptor interaction pathway (high levels 
of expression, red; low expression, blue). dEG, differentially expressed gene.
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Effect of eleutheroside B1 treatment on pathway regulation 
in influenza A virus‑infected lung epithelial A549 cells. The 
gene lists generated for influenza A virus‑infected human 
lung epithelial A549 cells in the absence or presence of 
eleutheroside B1 treatment revealed large differences in 
the number and the type of genes that were transcription-
ally activated. To gain an improved understanding of the 
host cell response to influenza virus infection at 24 h, 
the 1,871 dEGs (958 upregulated and 913 downregulated 
genes) between the PR8 and the PR8 + eleu groups were 
characterized by performing an enrichment analysis 
according to biological process, cellular composition and 
molecular function. GO enrichment analysis indicated that 
numerous dEGs were involved in molecular function and 
biological processes, and these results are presented in 
Table III. The GO enrichment results revealed that eleu-
theroside B1 recruited molecular function and biological 
process genes in the host to inhibit the infection of influ-
enza virus. KEGG pathway enrichment analysis suggested 
that these dEGs were associated with the immune system, 
glycan biosynthesis and metabolism, signaling molecules 
and their interaction, transcription (e.g., of the chemokine 
signaling pathway), various types of N-glycan biosyn-
thesis, cytokine‑cytokine receptor interaction, and RNA 
polymerase function, which are host-response pathways 
that are activated in response to influenza virus infection 
(Fig. 1). Twelve DEGs were enriched in cytokine‑cytokine 
receptor interactions. Of these dEGs, bone morphogenetic 
protein receptor type 1B (BMPR1B), interleukin‑6 signal 
transducer (IL6ST), interferon γ receptor 2 (IFNGR2), 
interleukin‑1 receptor‑associated protein (IL1RAP) and 
erythropoietin receptor (EPOR) have been reported to be 
involved in the host immune response to virus infections 
(Fig. 2). BMPR1B is a host gene, the levels of which change 
during the process of influenza virus infection (23), and this 
was expressed at a 548-fold higher level compared with the 
PR8 group. IFNGR2 is the upstream molecule in the inter-
feron γ (IFN-γ) signaling pathway, which is affected by the 
influenza virus (24). Compared with the PR8 group, there 
was a 1,369-fold upregulation of the IFNGR2 gene in the 
PR8 + eleu group. EPOR is crucial for the phosphorylation 
of signal transducer and activator of transcription (STAT) 
5, which acts as an important molecule in the Janus kinase 
(JAK)-STAT signaling pathway (22). Influenza A virus 
Figure 3. Enrichment analysis results of DEGs regulated by eleutheroside B1 treatment in the chemokine signaling pathway. The heat‑map shows the 24 DEGs 
that were regulated by eleutheroside B1 treatment among three samples in the chemokine signaling pathway (high levels of expression, red; low expression, 
blue). dEG, differentially expressed gene. 
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directly interferes with IFN-γ-stimulated signal transduc-
tion via this pathway, which enables the virus to inhibit 
IFN-γ-inducible gene expression (24). In the present study, 
levels of the EPOR gene were found to be upregulated by 
255-fold. IL1RAP is a co-receptor of the IL-1 receptor 
(IL1R1) and the IL-33 receptor (ST2), and is required for 
signaling through both receptor complexes. The inhibition 
of IL1RAP is also capable of blocking IL‑1 signaling, which 
disrupts the activation of nuclear factor (NF)-κB mediated 
by IL‑1 and IL‑33, and may inhibit influenza virus‑induced 
pro‑inflammatory reaction (25).
Influenza A virus infection in the lung is associated with 
a robust host inflammatory response and sustained elevated 
levels of inflammatory immune mediators (26), whereas 
certain natural product compounds have been demonstrated 
to exhibit anti‑inflammatory effects (27,28). The DEG data 
associated with the chemokine signaling pathway (Fig. 3) 
confirmed our previous finding that eleutheroside B1 exhibits 
anti‑inflammatory activity against the influenza virus (14). 
The DEGs identified in the N‑glycan biosynthesis pathway 
suggest other ways in which eleutheroside B1 may work 
against the influenza virus. In the N-glycan biosynthesis 
pathway, there are only a small number of glycosyltransferases 
catalyzing different glycosidic linkages on different N‑glycans 
that exert a crucial role in cellular activity (29). The synthesis 
of influenza virus hemagglutinins has been reported to be 
involved in this process (30). In the present study, 12 enriched 
dEGs were identified in the major N-glycan biosynthesis 
pathway, 9 enriched dEGs were found in various other types 
of N-glycan biosynthesis pathways, and 3 genes were found 
in other glycan degradation pathways (Fig. 4), all of which 
are involved in glycan biosynthesis and metabolism. These 
included: UdP-N-acetylglucosaminyltransferase subunit 
(ALG13), mannosidase α class 2A member 2 (MAN2A2), 
mannosidase α class 2c member 1 (MAN2c1), chito-
biosyldiphosphodolichol β-mannosyltransferase (ALG1), 
and α-1,2-mannosyltransferase (ALG9). MAN2c1 has dual 
functions: One is associated with glycan catabolism, whereas 
the other is in apoptotic signaling, and its downregulation 
has been reported to delay cancer growth by inducing either 
mitotic arrest or apoptosis (31). MAN2c1 overexpression also 
results in synthesis of the non-glucosylated Man9GlcNAc2 
oligosaccharide precursor, which is transferred to the protein 
substrates more inefficiently, thereby resulting in protein 
Figure 4. Enrichment analysis results of dEGs regulated by eleutheroside B1 treatment in various N-glycan biosynthesis pathways. The heat-map shows the 9 
dEGs that were regulated by eleutheroside B1 treatment among three samples in various types of N-glycan biosynthesis pathway (high levels of expression, 
red; low expression, blue). dEG, differentially expressed gene. 
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underglycosylation (32). In the present study, MAN2c1 was 
upregulated 9-fold following eleutheroside B1 treatment.
RNA synthesis is a fundamental process in gene expression, 
and POLR2A, a housekeeping gene coding for the large subunit 
of RNA polymerase II (RNAPII) in RNA biosynthesis (33), 
is a host factor involved in RNAPII-dependent transcription 
and mRNA processing of the influenza virus (34). The RNA 
sequencing results of the present study revealed that POLR2A 
was downregulated by 16,384-fold following eleutheroside B1 
treatment.
POLR2A may interact with eleutheroside B1, as determined 
from the molecular docking assay. Over the course of the last 
three decades, specific inhibitors of certain enzymes associated 
with the N-glycan biosynthesis pathway have demonstrated 
their potential for antiviral and tumor therapy (35). Golgi 
MAN2A1 is a key enzyme, which acts late in the N‑glycan 
biosynthesis pathway and is a target in the development of anti-
cancer and antiviral therapies (36). Mannostatin A effectively 
blocked processing of the influenza viral hemagglutinin in 
cultured MdcK cells, causing the accumulation of hybrid-type 
protein‑linked oligosaccharides, a result which is in agreement 
with blocking Golgi mannosidase II (36). MAN2A1 inhibi-
tors are also extracted from plant sources and, therefore, the 
present study aimed to investigate whether MAN2A1 may be 
a potential target of eleutheroside B1. However, we did not 
identify the structure of human MAN2A1 and is not avail-
able in databases; therefore, the structure of D. melanogaster 
MAN2A1 was used in the present study. In the initial results, 
D. melanogaster MAN2A1 was docked with eleutheroside 
B1. In addition, the crystal structure of human MAN2A1 was 
established through homology modeling, and this predicted 
structure was used for docking assays with eleutheroside B1. 
Furthermore, a previous study by our research group had 
shown that eleutheroside B1 inhibited the polymerase activity 
of influenza virus (14). POLR2A is an important host factor 
that is involved in the polymerase activity of influenza virus, 
and is downregulated by eleutheroside B1. Therefore, POLR2A 
was also selected for further investigation.
Small molecules were docked to these selected proteins, 
and the docking scores were analyzed. In general, a compound 
that has a high docking score with the protein (Total Score 
and cScore) indicates that the compound may have potential 
activities against the targeted receptor (37). From the results 
of the docking study, it was possible to determine that the 
selected molecules exhibited good binding affinity towards 
the homologous proteins in the model. The specific scores are 
listed in Table IV.
To determine its potency, the best‑docked conforma-
tion of eleutheroside B1 was analyzed, and this molecular 
compound was found to bind to the inside of D. melano‑
gaster MAN2A1(3BVT) and human POLR2A(3d9N), based 
upon the hydrogen and hydrophobic interactions. If such 
features are identified, it demonstrates that the compound 
in question may be responsible for mediating biological 
activities. The docked conformations of eleutheroside 
B1 in the D. melanogaster MAN2A1(3BVT) and human 
POLR2A(3d9N) structures are illustrated in Figs. 5 and 6, 
respectively. The interaction analysis revealed that there are 
13 hydrogen bonds formed by eleutheroside B1 in the binding 
site of D. melanogaster MAN2A1(3BVT), and four hydrogen 
bonds formed by eleutheroside B1 in the binding site of 
human POLR2A(3d9N), together with two carbon-hydrogen 
bonds and two conventional hydrogen bonds. Other interac-
tions were also investigated, including van der Waals' forces, 
which contact the surrounding residues in the binding site 
of bovine serum antigen, including Arg-893, Leu-925, 
Arg-565, Leu-568, Arg-777, Glu-753, Trp-531, Arg-427 and 
Asp-930. Inspection of the molecular interactions revealed 
that hydrogen bonds and van der Waals' forces were the 
major factors influencing the stabilities of the eleutheroside 
B1-MAN2A1 and the eleutheroside B1-POLR2A complexes, 
which are illustrated in Figs. 5 and 6, respectively.
MAN2A1(3BVT) in this docking assay belongs to 
D. melanogaster, which has high sequence identity with 
human MAN2A1 (41% identity; 61% similarity) (38). A 
predicted crystal structure for the human MAN2A1 was also 
generated through homology modeling with docked eleu-
theroside B1, however this had a lower docking score (data 
not shown). Since the protein POLR2A is associated with a 
higher molecular docking score and is also of human origin, 
this protein was identified as a target protein for eleuthero-
side B1, and further experimental verification was performed 
at the cellular level.
Eleutheroside B1 modifies the CpG methylation levels of 
the POLR2A and MAN2A1 genes. Even in the molecular 
docking assay, human MAN2A1 did not match precisely with 
eleutheroside B1; however, the possibility of their biological 
interaction could not be excluded. Therefore, MAN2A1 and 
POLR2A were selected to examine the cpG methylation levels 
modified by eleutheroside B1. CpG islands were identified on 
the POLR2A and MAN2A1 promoters by sequence analysis 
(http://www.urogene.org/cgi-bin/methprimer/methprimer.cgi; 
Fig. 7). To investigate whether eleutheroside B1 modifies DNA 
methylation of POLR2A and MAN2A1, bisulfite‑sequencing 
PcR (BSP) was performed to quantitatively analyze the 
methylation levels of cpG sites in these genes in A549 cells 
incubated with or without eleutheroside B1 following infec-
tion with A/PR/8/34 (H1N1). Ten clones were selected for the 
analysis of each cpG site. The BSP analysis revealed that the 
average proportion of methylated cpGs of the POLR2A gene 
increased significantly (P<0.05) in A549 cells treated with eleu-
theroside B1 compared with the PR8 group (Fig. 7). However, 
no significant differences were identified for the proportion of 
methylated cpGs of the MAN2A1 gene between A549 cells 
with or without eleutheroside B1 treatment following infection 
with A/PR/8/34 (H1N1) (data not shown).
Table IV. Score of molecular docking.
Protein Total_Score cScORE UNIFIEd-cEcORER
MAN2A1 11.3029 5 3
POLR2A   9.0133 5 2
MAN2A1, mannosidase α class II member 1; POLR2A, RNA poly-
merase II subunit A.
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mRNA expression of host genes and virus genes are influ‑
enced by eleutheroside B1 treatment in A549 cells. To identify 
genes involved in novel pathways, such as various types of 
N-glycan biosynthesis and RNA polymerase function, the 
expression levels of host genes (MAN2A2, POLR2A) were 
detected. In glycan biosynthesis and metabolism, MAN2A1, 
MAN2A2, and MAN2c1 were identified as the important 
targets. MAN2A1 did not display a potential interaction with 
eleutheroside B1; MAN2A2, however, was involved in the 
various types of N-glycan biosynthesis pathways, whereas 
MAN2c1 was involved in other glycan degradation pathways. 
POLR2A demonstrated a marked potential interaction with 
eleutheroside B1 in the present study, and significant levels 
of expression were observed following influenza infection 
in A549 cells treated with eleutheroside B1, and influenza 
infection of the A549 cells in the RNA sequencing studies. 
Therefore, MAN2A2 and POLR2A were selected for deter-
mination of their expression levels. In addition, virus genes 
(PA, PB1, PB2, HA) in A/PR/8 (0.1 MOI)-infected A549 cells 
were also subjected to mRNA expression studies. The results 
demonstrated that the expression of host genes (MAN2A2, 
POLR2A) and virus genes (PA, PB1, PB2, HA) were decreased 
following eleutheroside B1 treatment at a concentration of 
100 µg/ml (Fig. 8). The expression levels of the influenza virus 
ribonucleoprotein (RNP) genes (PA, PB1, PB2) were down-
regulated by eleutheroside B1, a finding which was consistent 
with the results of a previous study, showing that eleutheroside 
B1 may target the influenza virus RNP and RNA polymerases 
in the host (14).
Discussion
Since a comprehensive analysis of the mechanisms underlying 
specific agents of TCM acting against influenza virus at the 
molecular level is difficult, RNA sequencing approaches may 
compensate for such draw‑backs, and provide a systematic 
analysis for the study of TcM pharmacology in order to 
identify the key molecular events that are linked with their 
efficacy (18).
In the RNA sequencing experiments of the present study, 
the 1,871 DEGs identified between the PR8 and PR8 + eleu 
groups were characterized by performing an enrichment 
analysis according to biological processes, cellular compo-
sition, and molecular function. These dEGs were involved 
Figure 5. Docking results of eleutheroside B1 and MAN2A1. (A) The predicted three‑dimensional structure of eleutheroside B1 (rendered by sticks) binding 
to MAN2A1. (B) The binding interaction of MAN2A1 and the surrounding residues, in which hydrogen donors are shown in pink and hydrogen acceptors are 
shown in green. The rest of the surface is white. (c) details of the interaction between eleutheroside B1 and MAN2A1, as well as the hydrophobicity, which 
is shown in a different color, from the highest lipophilic area (brown) to the highest hydrophilic area (blue). MAN2A1, mannosidase α class II member 1.
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in various types of N‑glycan biosynthesis, the chemokine 
signaling pathway, cytokine‑cytokine receptor interaction, 
and RNA polymerase function, which are host responses to 
influenza viral infection. The biosynthesis of N‑glycans is 
very complex in mammals, as is the glycosylation-mediated 
quality control of protein folding by N-glycans (39). 
Glycosylation has become an area of intensive study in recent 
years, due to its ability to impact viral biology. A previous 
study demonstrated that N-glycosylation of the influenza 
hemagglutinin serves an important role in the life cycle 
of the influenza virus (35). The present RNA sequencing 
results demonstrated that certain dEGs, including ALG13, 
MAN2A2, MAN2c1, ALG1, and ALG9, were enriched in 
glycan biosynthesis and metabolism. MAN2c1 overex-
pression also results in the synthesis of non-glucosylated 
Man9GlcNAc2 oligosaccharide precursor, which is trans-
ferred to the protein substrates rather inefficiently, thereby 
resulting in suboptimal protein glycosylation. In the present 
study, MAN2c1 was upregulated by 9-fold following 
eleutheroside B1 treatment. This finding indicated that 
eleutheroside B1 may regulate the N-glycosylation of the 
influenza hemagglutinin via this pathway, although further 
studies are required to confirm this phenomenon.
Cytokines are soluble extracellular proteins or glycopro-
teins that are crucial intercellular regulators and are involved in 
innate, as well as adaptive, inflammation of host defenses, cell 
growth, differentiation, cell death, angiogenesis, development 
and repair processes (40). Cytokines and cytokine receptor 
interaction networks are regarded as essential components of 
inflammation (41). In the current RNA sequencing studies, 12 
DEGs were enriched in cytokine‑cytokine receptor interac-
tions. These dEGs included BMPR1B, IL6ST, IFNGR2, 
IL1RAP, and EPOR, which have been reported to be involved 
in host immune response to viral infections. IL-6ST encodes 
membrane glycoprotein 130 (gp130). It is the common signal 
transducing component of the IL6 cytokine receptor family, 
which forms complexes with the ligand-binding receptor 
subunits of multiple IL6 cytokine family members, serving 
as an important activator of JAK-STAT signaling. IL-6ST has 
also been reported to be involved in the host response for the 
infection of influenza virus (42,43). These results suggested 
that eleutheroside B1 may inhibit influenza virus through 
Figure 6. Docking results of eleutheroside B1 and POLR2A. (A) The predicted three‑dimensional structure of eleutheroside B1 (rendered in sticks) binding 
to POLR2A. (B) The interaction between eleutheroside B1 and POLR2A, as well as the hydrophobicity, which is shown in a different color, from the highest 
lipophilic area (brown) to the highest hydrophilic area (blue). (c) The binding interaction of POLR2A and the surrounding residues, in which hydrogen donors 
are shown in pink and hydrogen acceptors are shown in green. The rest of the surface is white. POLR2A, RNA polymerase II subunit A.
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cytokine and cytokine receptor interaction networks, although 
more evidence is required to conclusively demonstrate this 
finding.
Chemokines are small soluble molecules that regulate 
cellular homing through molecular gradients (44). A previ-
ously published study reported that the chemokines, C‑C 
motif chemokine ligand 2 (CCL2)/monocyte chemoattrac-
tant protein 1 (MCP‑1), C‑X‑C motif chemokine ligand 8 
(CXCL8)/interleukin 8 (IL8), CXCL9/monokine induced 
by interferon-γ (MIG), and cXcL10/interferon γ-induced 
protein 10 (IP-10), are also associated with mortality caused 
by human and avian influenza viral infections (45). In the 
RNA sequencing results of the present study, certain dEGs 
were also identified in the chemokine signaling pathway, 
a finding which was consistent with our previous study 
showing that eleutheroside B1 exhibited anti‑inflammatory 
activity against the influenza virus (14).
The influenza virus polymerase performs numerous func-
tions during the virus' life cycle, suggesting that many cellular 
factors interact with this complex and are required for the 
viral genome's transcription and replication. POLR2A is one 
of the influenza virus polymerase‑interacting proteins, and is 
required for viral replication and transcriptional activity of 
the viral polymerase (34). In the RNA sequencing results, the 
levels of POLR2A were downregulated by 21,007-fold [logFc 
(PR8+eleu/PR8) = -14.3585910971] following eleutheroside 
B1 treatment. The influenza virus transcribes and replicates 
its genome inside the nucleus of infected cells, a process that 
requires viral RNA polymerase, including the three subunits 
PA, PB1, and PB2, as well as host cell factors to transcribe 
Figure 7. Prediction of cpG islands and effects of eleutheroside B1 on dNA methylation of POLR2A in virus-infected A549 cells. POLR2A, RNA poly-
merase II subunit A. The white circles are unmethylated sites and the black circles are methylated sites. *P<0.05 compared with the PR8 group.
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and replicate the viral genome. The cellular transcription 
factor POLR2A is required for virus replication and the tran-
scriptional activity of the viral polymerase. A previous study 
demonstrated that the depletion of POLR2A could reduce 
by 2‑fold the viral polymerase transcription of the influenza 
virus (34). In the current transcriptome data, eleutheroside 
B1 treatment also reduced the expression of POLR2A, which 
demonstrated that POLR2A may be a potential drug target for 
the inhibition of influenza virus. This result was consistent 
with our previous finding that eleutheroside B1 inhibited RNP 
mRNA expression and transcriptional activity of the viral 
polymerase (14).
Molecular docking methodology explores the behavior of 
small molecules in the binding pocket of a target protein, and 
calculates the ability of the compounds to act against a partic-
ular target (and their specificity). In modern drug discovery, 
molecular docking methodology serves an important role in 
predicting the orientation of the ligand, and provides poten-
tial leads for researchers to identify potential drugs and drug 
targets (46). In the molecular docking results in the present 
study, eleutheroside B1 was found to bind to the inside of the 
D. melanogaster MAN2A1(3BVT) and human POLR2A, 
but this was not the case for the predicted crystal structure 
of human MAN2A1. These findings indicated that POLR2A 
may be the potential target for the eleutheroside B1 against 
influenza virus infections in humans, which was in accordance 
with the RNA sequencing results.
MAN2A2 is an important enzyme in the N-glycan biosyn-
thesis pathway, and its proper functioning is required for the 
glycosyltransferases of influenza virus hemagglutinins (36). 
POLR2A is a housekeeping gene in RNA polymerase 
II-dependent transcription in hosts, and it is involved in the 
mRNA processing of influenza virus (33). PA, PB1, PB2, HA 
are four RNA segments of the influenza virus genome that 
are crucial for the genome‑packaging process of influenza 
virus (47). Similar to human genes, influenza virus must also 
pass its genome accurately on to the next generation to ensure 
the survival of the species (48). The results of the RT-qPcR 
assay revealed that the mRNA expression levels of MAN2A2, 
POLR2A, PA, PB1, PB2, and HA, which are principally 
involved in viral RNP function and virus replication, were all 
downregulated following eleutheroside B1 treatment. Even 
in the cells receiving treatment with eleutheroside B1 alone 
(i.e., no virus), effects on the expression levels of MAN2A2 
and POLR2A were also observed. These results indicated that 
eleutheroside B1 may affect certain factors associated with 
the N-glycan biosynthesis pathway and mRNA processing 
in the host, which leads to the inhibition of the production of 
influenza virus proteins.
Through recruiting proteins involved in gene repression or 
inhibiting the binding of transcription factors to dNA, dNA 
methylation is involved in the regulation of gene expression, 
mRNA splicing, and genomic stability (49). In general, dNA 
methylation may block the expression of a gene (50). DNA 
methylation analysis revealed that eleutheroside B1 increased 
the average proportion of methylated cpGs of the POLR2A 
gene significantly (P<0.05) in A549 cells with influenza virus 
infection, compared with the virus control cells. On the basis 
Figure 8. Effect of eleutheroside B1 on host and viral gene expression. (A and B) mRNA expression levels of the host genes (MAN2A2, POLR2A) and 
(c-F) the viral genes (HA, PB2, PB1, PA) was examined in the virus-infected A549 cells, with or without eleutheroside B1 treatment. *P<0.05 compared with 
the PR8 group. MAN2A1, mannosidase α class II member 1; POLR2A, RNA polymerase II subunit A.
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of our previous study (14) and the results of the present study, 
it can be hypothesized that eleutheroside B1 may affect the 
POLR2A gene dNA methylation pattern to inhibit the produc-
tion of the influenza virus genome. For the D. melanogaster 
MAN2A1(3BVT), the molecular docking results demonstrated 
that it was a good match with eleutheroside B1, but this was 
not true for the human MAN2A1. Even in the dNA methyla-
tion analysis, the dNA methylation levels of human MAN2A1 
gene were not influenced by eleutheroside B1 treatment. 
Therefore, the POLR2A gene is more likely to be the target of 
eleutheroside B1 compared with the MAN2A1 gene. However, 
additional studies are required in order to confirm the detailed 
mechanism of action.
In conclusion, using RNA sequencing technology, the 
present study demonstrated that eleutheroside B1 may inhibit 
influenza virus via the chemokine signaling pathway, cyto-
kine‑cytokine receptor interactions, N‑glycan biosynthesis, 
and RNA polymerase, and that several dEGs involved in 
these pathways are interconnected as a part of a network, as 
illustrated in Fig. 9. The changes in the chemokine signaling 
pathway and in cytokine‑cytokine receptor interactions 
revealed in the present study are consistent with our previous 
study, which demonstrated that the expression levels of several 
cytokines were all downregulated by eleutheroside B1 (14). 
Previous studies have also reported that compounds extracted 
from herbs exert a role in the inflammatory process, and 
influence the immune system for the prevention of infectious 
disease (51,52). In the present study, it was observed that eleu-
theroside B1 targeted the POLR2A gene in order to affect the 
expression of viral polymerase. Therefore, eleutheroside B1 
may be a promising agent for the prevention and treatment of 
influenza A virus.
Figure 9. Protein interaction map for differentially expressed genes in target pathways. The map was constructed using the String website (https://string-db.
org/).
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